


PERSONAL INFORMATION

Chiara Lanzillotta *Pharm.D., Ph.D.*

 Department of Biochemical Sciences "A. Rossi Fanelli"
 Sapienza University of Rome
 Piazzale Aldo Moro 5, 00185, Rome, Italy



 N/A
 Chiara.lanzillotta@uniroma1.it

WORK EXPERIENCE

From February 2018 – to February 2021
Post-doctoral Researcher
 Department of Biochemical Sciences
 "A. Rossi Fanelli" Sapienza University
 of Rome
 Rome, Italy



SAPIENZA
 UNIVERSITÀ DI ROMA

From May 2016 – to June 2017
Research Scholar
 (a) Department of Molecular and
 Biomedical Pharmacology in the
 Sanders-Brown Center on Aging and
 (b) Department of Chemistry,
 Laboratory of Neurochemistry
 University of Kentucky, Lexington,
 Kentucky, USA



From November 2014 – to November 2017
Ph.D. Candidate in Biochemistry
 Department of
 Biochemical Sciences "A. Rossi
 Fanelli" Sapienza University of Rome
 Rome, Italy



SAPIENZA
 UNIVERSITÀ DI ROMA

From February 2013 – to July 2014
Visiting Student
 Department of
 Biochemical Sciences "A. Rossi
 Fanelli" Sapienza University of Rome
 Rome, Italy



SAPIENZA
 UNIVERSITÀ DI ROMA

From May 2012 – to November 2013 Pharmacy Training Pharmacy Frascati (RM), Italy



EDUCATION AND TRAINING

- February 2018 **Post-doctoral Researcher**
Department of Biochemical Sciences “A. Rossi-Fanelli” Sapienza University of Rome, Italy
- December 2017 **Ph.D. in Biochemistry**
Department of Biochemical Sciences “A. Rossi-Fanelli” Sapienza University of Rome, Italy
- December 2014 **National Qualification as Pharmacist**
Faculty of Pharmacy, Sapienza University of Rome, Italy
- July 2014 **Doctor in Pharmaceutical Chemistry and Technology**
Faculty of Pharmacy, Sapienza University of Rome, Italy
- 2007 **Secondary School Diploma**
Liceo Scientifico “Bruno Touschek” – Grottaferrata (RM) Italia

PERSONAL SKILLS

Mother tongue Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	C1

HONORS AND AWARDS

- June 2019 *Travel award 3rd International Conference Trisomy 21 Research Society Barcelona 2019*
- January 2017 *Travel Grant Sapienza*

November 2016 *SIB travel Grant* Italian Society of Biochemistry and Molecular Biology (SIB)

PROFESSIONAL MEMBERSHIPS

2017-present members of T21RS

2014-present Italian Society of Biochemistry (SIB)

INVITED SPEAKER

- *15th International Conference on Alzheimer's and Parkinson's Diseases ADPDTM 2021. March 9- March 14, 2021. Virtual Conference (COVID 19). Oxidative stress links brain Insulin resistance and mitochondrial defects in Down syndrome brain early in life: implication for neurodegeneration*

- *4th Conference Sindrome di Down dalla diagnosi alla terapia. Virtual edition. 16-17 Ottobre 2020 Analisi del profilo proteomico in cellule mononucleate periferiche nella sindrome di Down: una finestra di osservazione verso il danno cerebrale*

- *3th Conference Sindrome di Down dalla diagnosi alla terapia 18-19 Ottobre 2019 Napoli. Alterazioni dell'omeostasi proteica nella T21.*

- *3th International Conference on Alzheimer's and Parkinson's Diseases ADPDTM 2017 March 29-April 2, 2017 in Vienna, Austria. The Unfolded Protein Response: a major early participant in the development of Alzheimer-like neuropathology in Down syndrome mice*

- *58° National Meeting of the Italian Society of Biochemistry and Molecular Biology (September 2015, Urbino, Italy). "Ubiquitin-bound protein profile in human brain from Down Syndrome individuals' prior and after the development of Alzheimer-like dementia"*

2014-2021: number of selected abstracts: 25

PROFESSIONAL EXPERTISE

Surgery and Tissue Processing: High experience with Small Animal Surgery, Brain dissection

Microscopy: Histochemistry, Immunohistochemistry, BrdU, Immunofluorescence

Behavioural Training: Radial maze test, novel object

Cell culture: Primary Neurons

Cell Lines (M17, iHEK, SHSY5, C33A, HeLa, SiHa)

Molecular Biology: DNA extraction, RT-PCR, Real Time PCR, Western Blot analysis, Proteomics and Redox Proteomics

Other Methods: ELISA, Reactive oxygen species assays.

SCIENTIFIC COLLABORATIONS

Prof. Jose F. Abisambra, Department of Neuroscience Center for Translational Research in Neurodegenerative Disease, Gainesville, FL (USA)

PUBLICATIONS LIST

[1] **C. Lanzillotta**, F. Di Domenico, Stress responses in Down syndrome neurodegeneration: state of the art and therapeutic molecules, *Biomolecules* 11(2), 266 (2021)

Citations= 0; Impact factor= 4.082

[2] **C. Lanzillotta**, A. Tramutola, G. Di Giacomo, F. Marini, D.A. Butterfield, F. Di Domenico, M. Perluigi, E. Barone, Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome, *Free Radic Biol Med* 165 (2021) 152-170.

Citations= 1; Impact factor= 6.170

[3] S.A. Koren, M.J. Hamm, R. Cloyd, S.N. Fontaine, E. Chishti, **C. Lanzillotta**, J. Rodriguez-Rivera, A. Ingram, M. Bell, S.M. Galvis-Escobar, N. Zulia, F. Di Domenico, D. Duong, N.T. Seyfried, D. Powell, M. Vandsburger, T. Frolinger, A.M.S. Hartz, J. Koren, 3rd, J.M. Axten, N.J. Laping, J.F. Abisambra, Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy, *Int J Mol Sci* 22(3) (2021).

Citations= 1; Impact factor= 4.556

[4] **C. Lanzillotta**, I. Zuliani, A. Tramutola, E. Barone, C. Blarzino, V. Folgiero, M. Caforio, D. Valentini, A. Villani, F. Locatelli, D.A. Butterfield, E. Head, M. Perluigi, J.F. Abisambra, F. Di Domenico, Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention, *Progr Neurobio* (2021) 101892.

Citations= 4; Impact factor= 9.371

[5] I. Zuliani, **C. Lanzillotta**, A. Tramutola, A. Francioso, S. Pagnotta, E. Barone, M. Perluigi, F. Di Domenico, The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome, *Neurotherapeutics* (2020) head for publication.

Citations= 1; Impact factor= 6.035

[6] Bouzidi A, Magnifico MC, Paiardini A, Macone A, Boumis G, Giardina G, Rinaldo S, Liberati FR, Lauro C, Limatola C, **C. Lanzillotta**, Tramutola A, Perluigi M, Sgarbi G, Solaini G, Baracca A, Paone A, Cutruzzolà F. Cytosolic serine hydroxymethyltransferase controls lung adenocarcinoma cells migratory ability by modulating AMP kinase activity. *Cell Death Dis.* 2020 Nov 26;11(11):1012. doi: 10.1038/s41419-020-03215-0. PMID: 33243973

Citations= 0; Impact Factor=6.304

[7] **C. Lanzillotta**, V. Greco, D. Valentini, A. Villani, V. Folgiero, M. Caforio, F. Locatelli, S. Pagnotta, E. Barone, A. Urbani, F. Di Domenico, M. Perluigi, Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children, *Antioxidants (Basel)* 9(11) (2020).

Citations= 1; Impact factor= 4.610

[8] **C. Lanzillotta**, I. Zuliani, C. Vasavda, S.H. Snyder, B.D. Paul, M. Perluigi, F. Di Domenico*, E. Barone, BVR-A Deficiency Leads to Autophagy Impairment through the Dysregulation of AMPK/mTOR Axis in the Brain-Implications for Neurodegeneration, *Antioxidants (Basel)* 9(8) (2020).

Citations= 2; Impact factor= 4.610

[9] A. Tramutola, **C. Lanzillotta**, F. Di Domenico, E. Head, D.A. Butterfield, M. Perluigi, E. Barone, Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome, *Neurobiol Dis* 137 (2020) 104772.

Citations= 16; Impact factor= 5.332

[10] A. Tramutola, S. Falcucci, U. Brocco, F. Triani, **C. Lanzillotta**, M. Donati, C. Panetta, F. Luzi, F. Iavarone, F. Vincenzoni, M. Castagnola, M. Perluigi, F. Di Domenico, F. Marco, Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression, *Cancers (Basel)* 12(1) (2020).

Citations= 0; Impact factor= 5.326

[11] **C. Lanzillotta**, F. Di Domenico, M. Perluigi, D.A. Butterfield, Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives, *CNS Drugs* (2019).
Citations= 10; Impact factor= 4.192

[12] F. Di Domenico, A. Tramutola, E. Barone, **C. Lanzillotta**, O. Defever, A. Arena, I. Zuliani, C. Foppoli, F. Iavarone, F. Vincenzoni, M. Castagnola, D.A. Butterfield, M. Perluigi, Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome, *Redox Biol* (2019) 101162.
Citations= 17; Impact factor= 9.986

[13] F.A. Cimini, A. Arena, I. Barchetta, A. Tramutola, V. Ceccarelli, **C. Lanzillotta**, M. Fontana, L. Bertocchini, F. Leonetti, D. Capoccia, G. Silecchia, C. Di Cristofano, C. Chiappetta, F. Di Domenico, M.G. Baroni, M. Perluigi, M.G. Cavallo, E. Barone, Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity, *Biochim Biophys Acta Mol Basis Dis* 1865(6) (2019) 1490-1501.
Citations= 14; Impact factor= 4.328

[14] N. Sharma, A. Tramutola, **C. Lanzillotta**, A. Arena, C. Blarzino, T. Cassano, D.A. Butterfield, F. Di Domenico, M. Perluigi, E. Barone, Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease, *Neurobiol Dis* 125 (2019) 176-189.
Citations= 22; Impact factor=5.227

[15] A. Tramutola*, **C. Lanzillotta***, E. Barone, A. Arena, I. Zuliani, L. Mosca, C. Blarzino, D.A. Butterfield, M. Perluigi, F. Di Domenico, Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome, *Transl Neurodegener* 7 (2018) 28.
***Co-Corresponding author**
Citations= 35; Impact factor= 5.534

[16] F. Di Domenico, **C. Lanzillotta**, A. Tramutola, Therapeutic potential of rescuing protein O-GlcNAcylation in tau-related pathologies, *Expert Rev Neurother* 19(1) (2019) 1-3.
Citations= 5; Impact factor= 3.453

[17] A. Tramutola, G. Abate, **C. Lanzillotta**, F. Triani, E. Barone, F. Iavarone, F. Vincenzoni, M. Castagnola, M. Marziano, M. Memo, E. Garrafa, D.A. Butterfield, M. Perluigi, F. Di Domenico*, D. Uberti, Protein nitration profile of CD3(+) lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection, *Free Radic Biol Med* 129 (2018) 430-439.
Citations= 12; Impact factor= 6.17

[18] A. Tramutola, N. Sharma, E. Barone, **C. Lanzillotta**, A. Castellani, F. Iavarone, F. Vincenzoni, M. Castagnola, D.A. Butterfield, S. Gaetani, T. Cassano, M. Perluigi, F. Di Domenico, Proteomic identification of altered protein O-GlcNAcylation in a triple

transgenic mouse model of Alzheimer's disease, *Biochim Biophys Acta Mol Basis Dis* 1864(10) (2018) 3309-3321.

Citations=15; Impact factor= 4.328

[19] **C. Lanzillotta**, A. Tramutola, S. Meier, F. Schmitt, E. Barone, M. Perluigi, F. Di Domenico, J.F. Abisambra, Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models, *J Alzheimers Dis* 62(1) (2018) 347-359.

Citations= 11; Impact factor= 3.731

[20] S.N. Fontaine, A. Ingram, R.A. Cloyd, S.E. Meier, E. Miller, D. Lyons, G.K. Nation, E. Mechas, B. Weiss, **C. Lanzillotta**, F. Di Domenico, F. Schmitt, D.K. Powell, M. Vandsburger, J.F. Abisambra, Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach, *Neurobiol Aging* 56 (2017) 78-86.

Citations= 10; Impact factor= 5.117

[21] A. Tramutola, **C. Lanzillotta**, F. Di Domenico, Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies, *Expert Rev Neurother* 17(1) (2017) 33-45.

Citations= 34; Impact factor= 3.149

[22] A. Tramutola, **C. Lanzillotta**, M. Perluigi, D.A. Butterfield. Oxidative stress, protein modification and Alzheimer disease. *Brain Res Bull.* 2016 Jun 15. Review.

Citations= 112; Impact Factor=3.440

[23] A. Tramutola, G. Pupo, **F. Di Domenico**, E. Barone, A. Arena, C. Lanzillotta, D. Brokekaart, C. Blarzino, E. Head, D.A. Butterfield, M. Perluigi, Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype, *J Alzheimers Dis* 52(1) (2016) 359-371.

Citations= 20; Impact factor=3.731

[24] A. Tramutola, C. Lanzillotta, A. Arena, E. Barone, M. Perluigi, **F. Di Domenico**, Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome, *Neurodegener Dis* 16(1-2) (2016) 62-8.

Citations=25; Impact factor= 2.842